| Entera Bio Announces First Quarter 2025 Financial Results and Business Updates |
JERUSALEM, May 09, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key business updates for the quarter ended March 31, 2025. |
globenewswire.com |
2025-05-09 20:05:00 |
Czytaj oryginał (ang.) |
| Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates |
JERUSALEM, March 28, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, today reported financial results and key business achievements for the year ended December 31, 2024. |
globenewswire.com |
2025-03-28 18:05:00 |
Czytaj oryginał (ang.) |
| OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders |
MIAMI and JERUSALEM, March 17, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, entered into a collaboration and license agreement to advance into the clinic the first oral dual agonist GLP-1/glucagon peptide as a once-daily tablet treatment for patients with obesity, metabolic and fibrotic disorders. The program combines OPKO's proprietary long-acting oxyntomodulin analog (OPK-88006) and Entera's proprietary N-Tab™ technology. Favorable pharmacodynamic, pharmacokinetic and bioavailability data in vivo were reported in September 2024. The companies expect to file an Investigational New Drug application with the U.S. Food and Drug Administration (FDA) later this year. |
globenewswire.com |
2025-03-17 10:00:00 |
Czytaj oryginał (ang.) |
| Entera Bio to Participate in Upcoming Events |
JERUSALEM, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of oral peptide and protein replacement therapies in tablet form, today announced that the Company will participate at the following conferences. |
globenewswire.com |
2025-02-24 10:30:00 |
Czytaj oryginał (ang.) |
| Entera Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference |
JERUSALEM, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, announced that it will participate and be available for investor meetings at the Oppenheimer 35th Annual Healthcare Life Sciences Conference being held February 11 – 12, 2025 in a virtual format. |
globenewswire.com |
2025-01-27 10:00:00 |
Czytaj oryginał (ang.) |
| Entera Bio Ltd. (ENTX) Reports Q3 Loss, Tops Revenue Estimates |
Entera Bio Ltd. (ENTX) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.05. |
zacks.com |
2024-11-08 20:15:21 |
Czytaj oryginał (ang.) |
| Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates |
JERUSALEM, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of oral peptides and small therapeutic proteins, today reported financial results and key business updates for the quarter ended September 30, 2024. |
globenewswire.com |
2024-11-08 18:05:00 |
Czytaj oryginał (ang.) |
| ENTX & OPK Stock May Gain Following Positive PK/PD Research Data |
Entera and OPKO Health announce positive PK/PD results from their ongoing collaborative research focused on developing the first oral dual agonist GLP-1/glucagon peptide. |
zacks.com |
2024-09-26 17:56:09 |
Czytaj oryginał (ang.) |
| Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders |
JERUSALEM and MIAMI, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (Entera), a leader in the development of orally delivered peptides, and OPKO Health, Inc. (NASDAQ: OPK) (OPKO) announced today topline pharmacokinetic/pharmacodynamic (PK/PD) results from their ongoing collaborative research combining a proprietary long-acting oxyntomodulin (OXM) analog developed by OPKO and Entera's proprietary N-Tab™ technology. The program is focused on developing the first oral dual agonist GLP-1/glucagon peptide as a potential once-daily treatment for patients with obesity, metabolic and fibrotic disorders. OXM is a naturally occurring peptide hormone found in the small intestine that acts to suppress appetite and induce weight loss. |
globenewswire.com |
2024-09-25 12:30:00 |
Czytaj oryginał (ang.) |
| Is Entera Bio (ENTX) Stock Outpacing Its Medical Peers This Year? |
Here is how Entera Bio Ltd. (ENTX) and argenex SE (ARGX) have performed compared to their sector so far this year. |
zacks.com |
2024-09-18 14:46:24 |
Czytaj oryginał (ang.) |
| Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year? |
Here is how Entera Bio Ltd. (ENTX) and Akebia Therapeutics (AKBA) have performed compared to their sector so far this year. |
zacks.com |
2024-09-02 14:40:28 |
Czytaj oryginał (ang.) |
| Entera Bio to Participate in Upcoming Investor and Scientific Conferences |
JERUSALEM, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, today announced that management will be participating in the following investor and scientific conferences: |
globenewswire.com |
2024-08-20 12:00:00 |
Czytaj oryginał (ang.) |
| All You Need to Know About Entera Bio (ENTX) Rating Upgrade to Buy |
Entera Bio (ENTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2024-08-15 17:06:07 |
Czytaj oryginał (ang.) |
| Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates |
JERUSALEM , Aug. 09, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, today reported financial results and key business updates for the quarter ended June 30, 2024. |
globenewswire.com |
2024-08-09 20:05:00 |
Czytaj oryginał (ang.) |
| 3 Meme Stocks to Buy and Hold for Potential 300% Returns in 3 Years |
Since 2021, meme stocks have been massive wealth creators for high-risk investors. During this period, dozens of meme stocks have delivered 5x to 10x returns within a few quarters. |
investorplace.com |
2024-07-23 10:28:00 |
Czytaj oryginał (ang.) |
| 3 Meme Stocks That Can Surge by 200% Before 2025 |
The S&P 500 index is trading near record highs, and the overall outlook for the market is likely to remain bullish. While GDP growth has decelerated, the markets seem to be discounting multiple rate cuts in the next 12 to 18 months. |
investorplace.com |
2024-07-08 19:53:20 |
Czytaj oryginał (ang.) |
| 3 Clinical-Stage Biotech Stocks to Buy for Multibagger Returns |
One of the ways to make millions from the market is to identify and invest in early-stage companies. If the business takes off, multi-fold returns are in the offering. |
investorplace.com |
2024-07-02 21:05:56 |
Czytaj oryginał (ang.) |
| 3 Meme Stocks to Buy on the Dip: June 2024 |
When meme stocks start skyrocketing, it's difficult to find a good entry point. Already, examples of a big rally in meme stocks happened in the recent past. |
investorplace.com |
2024-06-25 20:37:07 |
Czytaj oryginał (ang.) |
| 7 Penny Stocks to Turn $3 Into $1 Million Within 36 Months |
A few penny stocks have already surged recently on the back of an impending meme frenzy. Other penny stocks to buy have remained relatively subdued. |
investorplace.com |
2024-06-20 16:38:50 |
Czytaj oryginał (ang.) |
| Rag to Riches: 3 Penny Stocks That Could Make Early Investors Rich |
There are penny stocks to buy that represent purely speculative bets. In a meme frenzy, these stocks can deliver multibagger returns in the blink of an eye. |
investorplace.com |
2024-06-20 10:47:00 |
Czytaj oryginał (ang.) |
| 3 Penny Stocks to Turn $50,000 Into $1 Million: June 2024 |
Investors looking for stocks with millionaire-maker potential must go overweight on growth and penny stocks. When it comes to penny ideas, the thing that comes to mind is speculation or a meme frenzy. |
investorplace.com |
2024-06-17 17:00:00 |
Czytaj oryginał (ang.) |
| Under-$10 Picks: 3 Biotech Stocks That Can Double Before the End of 2024 |
Biotech stocks are always interesting from a trading perspective. With dozens of companies in the clinical-stage, positive news from trials can be a big catalyst for a scintillating rally. |
investorplace.com |
2024-06-10 23:22:44 |
Czytaj oryginał (ang.) |
| Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar |
In a meme frenzy, any positive news related to a company has a magnified impact on the stock price. In the euphoria of 2021, companies with ambitious growth plans skyrocketed. |
investorplace.com |
2024-06-07 11:30:00 |
Czytaj oryginał (ang.) |
| Has Entera Bio (ENTX) Outpaced Other Medical Stocks This Year? |
Here is how Entera Bio Ltd. (ENTX) and PetIQ (PETQ) have performed compared to their sector so far this year. |
zacks.com |
2024-06-03 14:41:29 |
Czytaj oryginał (ang.) |
| The Next Novavax? 3 Biopharma Stocks to Buy Before They Boom |
Novavax (NASDAQ: NVAX ) stock was among the laggards in the race for the vaccine against COVID-19. Unsurprisingly, NVAX stock plunged from highs of $320 in 2021 to recent lows of $3.5. |
investorplace.com |
2024-05-23 10:45:00 |
Czytaj oryginał (ang.) |